[en] We report the case of a child with catecholaminergic polymorphic ventricular tachycardia, who had inappropriate electric shocks by an implantable cardioverter defibrillator and from recurrence of arrhythmias despite an appropriate β-blocking treatment. An additional treatment by flecainide completely suppressed inappropriate shocks due to sinusal tachycardia and ventricular tachyarrhythmias. We briefly discuss the potentially interesting effect of flecainide in this specific arrhythmia.
Disciplines :
Pediatrics
Author, co-author :
Jacquemart, Caroline ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pédiatrie ; Division of Pediatric Cardiology, Queen Fabiola Children's University Hospital, HUDERF, Free University of Brussels, ULB, Brussels, Belgium
Ould Abderrahmane, Fazia; Division of Pediatric Cardiology, Queen Fabiola Children's University Hospital (ULB), B - 1020 Brussels, Belgium
Massin, Martial M; Division of Pediatric Cardiology, Queen Fabiola Children's University Hospital (ULB), B - 1020 Brussels, Belgium
Language :
English
Title :
Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
D.P. Zipes, A.J. Camm, and M. Borggrefe ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace 8 2006 746
K. Ylänen, T. Poutanen, A. Hiippala, H. Swan, and M. Korppi Catecholaminergic polymorphic ventricular tachycardia Eur J Pediatr 169 2010 535
C. van der Werf, A.H. Zwinderman, and A.A. Wilde Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments Europace 14 2012 175
C. van der Werf, P.J. Kannankeril, and F. Sacher Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia J Am Coll Cardiol 57 2011 2244
H. Watanabe, N. Chopra, and D. Laver Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans Nat Med 15 2009 380
M. Massin, P. Leroy, J.P. Misson, and P. Lepage Catecholaminergic polymorphic ventricular tachycardia in a child: an often unrecognized diagnosis Arch Pediatr 10 2003 524
M. Lewandowski, M. Strelinski, and A. Maciag Long-term follow-up of children and young adults treated with implantable cardioverter-defibrillator: the authors' own experience with optimal implantable cardioverter-defibrillator programming Europace 12 2010 1245
F.A. Hilliard, D.S. Steele, and D. Laver Flecainide inhibits arrhythmogenic Ca2 + waves by open state block of ryanodine receptor Ca2 + release channels and reduction of Ca2 + spark mass J Mol Cell Cardiol 48 2010 293
